Neoplasms, Germ Cell and Embryonal Clinical Trial
Official title:
Phase II Study of Oxaliplatin Plus Bevacizumab Salvage Chemotherapy in Patients With Germ Cell Tumors
The purpose of this study is to evaluate the effectiveness of oxaliplatin and bevacizumab in patients with refractory or relapsed germ cell tumors.
This study proposes to look at the established combination of oxaliplatin and bevacizumab as used in colorectal cancer in refractory germ cell tumor patients. Oxaliplatin is a drug of known activity. Although bevacizumab has no single agent data, it combines dramatically well with numerous chemotherapy drugs, such as oxaliplatin increasing response rates and improving survival. Furthermore, VEG-F appears to be an important target in germ cell tumors as it does in so many other types of solid tumors. We will be using the identical dosages of oxaliplatin + bevacizumab as has been utilized in previously treated colorectal cancer, without the addition of 5-FU + leucovorin. This dose and schedule has been proven to be safe and effective. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02863003 -
Multicenter Database of Patients With Germ Cell Tumor
|
||
| Active, not recruiting |
NCT03911388 -
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02533765 -
Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor
|
Phase 2 | |
| Completed |
NCT02679950 -
Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse
|
||
| Completed |
NCT03403777 -
Avelumab in Refractory Testicular Germ Cell Cancer.
|
Phase 2 | |
| Recruiting |
NCT04949282 -
Spanish Series of Patients Treated With the Radionuclide Lutetium177
|
||
| Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT04657315 -
Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02839694 -
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy
|
Phase 1 | |
| Completed |
NCT03012620 -
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
|
Phase 2 | |
| Active, not recruiting |
NCT04222972 -
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
|
Phase 3 | |
| Completed |
NCT00611962 -
Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin
|
Phase 2 | |
| Enrolling by invitation |
NCT04697446 -
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
|
||
| Terminated |
NCT02859415 -
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
|
Phase 1/Phase 2 | |
| Available |
NCT05592743 -
Vorasidenib Expanded Access Program
|